

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)



(10) International Publication Number
WO 2023/086929 A1

- (51) **International Patent Classification:**
C07K 19/00 (2006.01) *C07K 14/70578* (2006.01)
A61K 38/16 (2006.01)
- (21) **International Application Number:**
PCT/US2022/079702
- (22) **International Filing Date:**
11 November 2022 (11.11.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/278,567 12 November 2021 (12.11.2021) US
63/371,083 11 August 2022 (11.08.2022) US
- (71) **Applicant:** SHATTUCK LABS, INC. [US/US]; 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US).
- (72) **Inventors:** PANDITE, Arundathy; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). RANGWALA, Fatima; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). LAMP-KIN, Thomas; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). SCHREIBER, Taylor; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). FROMM, George; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). DE SILVA, Suresh; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US).

(74) **Agent:** ALTIERI, Stephen, L. et al.; Morgan, Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** SIRP1A - AND CD40L-BASED CHIMERIC PROTEINS




FIG. 10A

(57) **Abstract:** The present disclosure relates, in part, to compositions and methods, including chimeric proteins, that find use in the treatment of disease, such as immunotherapies for cancer.

WO 2023/086929 A1

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*